Regeneron (REGN) Reports Updates on Phase 3 Libtayo (cemiplimab) Development Program in Advanced NSCLC

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/14/2026

1. ADBE
2. SPCX
3. USO
4. SPY
5. RH
6. NVDA
7. RKLB
8. CRM
9. MSFT
10. MRVL

Go back to Regeneron (REGN) Reports Updates on Phase 3 Libtayo (cemiplimab) Development Program in Advanced NSCLC

Regeneron Provides Updates on Phase 3 Libtayo® (cemiplimab) Development Program in Advanced Non-small Cell Lung Cancer

November 5, 2019 6:40 AM EST

TARRYTOWN, N.Y., Nov. 5, 2019 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today provided an update on the ongoing Phase 3 development program evaluating Libtayo® (cemiplimab), a PD-1 inhibitor, as monotherapy and combination therapy in first-line patients with advanced non-small cell lung cancer (NSCLC). Regeneron is currently... More